Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Adults were more likely than children to screen positive for a single autoantibody (4.0% vs. 2.6%) but less likely for multiple autoantibodies (0.83% vs. 2.8%; P < 0.001). Progression to stage 3 disease was lower in adults with single autoantibody positivity or stage 1 T1D than in children (5-year risks: single autoantibody, adults 8.2% vs. children 22%, P < 0.001; stage 1, adults 17% vs. children 47%, P < 0.001). However, adults with stage 2 T1D at initial staging oral glucose tolerance test had comparable 5-year progression risks to children (78% for both groups). A higher proportion of adults progressing to clinical diabetes were single autoantibody positive (40% vs. 15%; P < 0.0001); these individuals commonly had single glutamic acid decarboxylase positivity and had lower type 1 but higher type 2 genetic risk scores compared with multiple autoantibody positive adults. HbA1c and established risk indices more effectively identified progressors in adults compared with children. Autoantibody positive adult relatives have distinct autoantibody trajectories and progression risks compared with children, suggesting the need for tailored monitoring and intervention strategies.

What this study adds

Evidence grade: Low

The record lists 135,914 participants. This study compares adults and children at risk of type 1 diabetes and reports differences in autoantibody patterns and progression to diabetes, with no Alzheimer's disease outcomes. Reported effect size: 4.0%; 2.6%; 0.83%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Templeman, E. L., Ferrat, L. A., Thomas, N. J. M., Speake, C., Wherrett, D. K., Sherr, J. L., et al. (2025). Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study. Diabetes Care. https://doi.org/10.2337/dc25-0192

Vancouver

Templeman EL, Ferrat LA, Thomas NJM, Speake C, Wherrett DK, Sherr JL, et al. Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study. Diabetes Care. 2025. doi:10.2337/dc25-0192. PMID: 40694568.

BibTeX

@article{templeman2025-40694568,
  author  = {Templeman, Erin L. and Ferrat, Lauric A. and Thomas, Nicholas J. M. and Speake, Cate and Wherrett, Diane K. and Sherr, Jennifer L. and Wentworth, John M. and REDONDO, MARIA JOSE and others},
  title   = {{Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study}},
  journal = {Diabetes Care},
  year    = {2025},
  doi     = {10.2337/dc25-0192},
  pmid    = {40694568},
  url     = {https://doi.org/10.2337/dc25-0192}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study compares adults and children at risk of type 1 diabetes and reports differences in autoantibody patterns and progression to diabetes, with no Alzheimer's disease outcomes. It suggests that monitoring and intervention strategies for type 1 diabetes may need to differ between adults and children.

Study details

How this study scored 60/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 60 of 100.60 of 100 points earned40 not earned

Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Diabetes Care)
Journal's citation record 4 / 4 Diabetes Care: journal h-index 509 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 135,914 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 24 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 13.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Emily Kristen Sims: h-index 37 (OpenAlex, whole career)
Institution's track record 2 / 3 Yale University: institution h-index 1,927 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40694568)
Free to read 2 / 2 Free to read
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Prevention and risk from nearby years

Also in Prevention and risk

269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →